Selection and validation of hybridoma clones for optimal signal-to-noise ratio among a wide range of tissues.
Detailed profiling of antibody staining pattern in high range of tissues entities.
Beta-testing and validation by different independent labs.
Our core competence is to validate new antibody clones for sensitivity, specificity and prognostic significance on a high range of human tissues through our histopathology network. We believe that our „ULTRA-validation“ approach is enabling the identification of new antibodies that will make both diagnostic and clinical differences.
To face the high demand for new antibody clones to be used as biomarkers to phenotype tumors, we apply a new strategy to develop clones by integrating immunohistochemistry as early step in the hybridoma screening procedure.